Latest Form 4 insider transactions

NASDAQ
Amine Asmerom, Chief Accounting Officer of Chime Financial, Inc., sold 10,000 shares of common stock on August 4, 2026 for $25.00 per share.
NYSE
Scott Semel, Interim CLO & General Counsel of Skillsoft Corp., reported multiple transactions in common stock on August 1, 2026.
NASDAQ
Lisette Reynoso, Sr. Vice President of Consumer Portfolio Services, Inc., reported multiple transactions in common stock on August 3, 2026.
NASDAQ
Harpreet S. Dhaliwal, Chief Technical Ops Officer of Vaxcyte, Inc., sold 17,000 shares of common stock on August 5, 2026 for $55.00 per share.
NYSE
Arvind Nithrakashyap, Chief Technology Officer and a Director of Rubrik, Inc., sold 38,460 shares of common stock on August 3, 2026.
NYSE
Aurobind Satpathy, a Director of Ingersoll Rand Inc., purchased 11,538 shares of common stock on August 3, 2026 for $86.68 per share.
NASDAQ
Daniel D. Long, SVP, Drug Discovery of Septerna, Inc., sold 3,334 shares of common stock on August 3, 2026.
NASDAQ
Gwenn Hansen, Chief Scientific Officer of Nurix Therapeutics, Inc., sold 4,356 shares of common stock on August 5, 2026 for $25.00 per share.
NYSE
Rhonda Davenport, Chief Human Resources Officer of Azz Inc, reported multiple transactions in common stock on August 4, 2026.
NYSE
Amanpal Singh Bhutani, Chief Executive Officer and a Director of GoDaddy Inc., sold 4,500 shares of common stock on August 3, 2026 for $83.15 per share.
NYSE
Sameer Bhargava, a Director of StubHub Holdings, Inc., received 27,840 shares of common stock on August 3, 2026.
NASDAQ
John R. Schroer, Chief Financial Officer of Alumis Inc., sold 3,282 shares of common stock on August 3, 2026 for $26.37 per share.
NASDAQ
Aditya Vikram Rajkumar, Chief Operating Officer of Groupon, Inc., reported multiple transactions in common stock on August 3, 2026.
NASDAQ
Sanam Pangali, Chief Legal Officer of Alumis Inc., sold 1,364 shares of common stock on August 3, 2026 for $26.37 per share.
NASDAQ
Sardar Biglari and 5 others reported changes in beneficial ownership of El Pollo Loco Holdings, Inc. common stock on August 3, 2026.
NYSE
Sardar Biglari and 5 others reported changes in beneficial ownership of Biglari Holdings Inc. common stock on August 3, 2026.
NASDAQ
Roy C. Hardiman, Chief Business & Strategy Ofcr of Alumis Inc., sold 2,692 shares of common stock on August 3, 2026 for $26.37 per share.
NASDAQ
Teri Robinson, Exec. Vice President of Consumer Portfolio Services, Inc., reported multiple transactions in common stock on August 3, 2026.
NASDAQ
Catrina Marie Ralston, Sr. Vice President of Consumer Portfolio Services, Inc., reported multiple transactions in common stock on August 3, 2026.
NASDAQ
David M Goldstein, Chief Scientific Officer of Alumis Inc., sold 2,596 shares of common stock on August 3, 2026 for $26.37 per share.
NASDAQ
Robert M Kimmitt, a Director of Meta Platforms, Inc., sold 500 shares of common stock on August 3, 2026 for $561.56 per share.
NYSE
Diane Bonina, VP, Gen'l Counsel & Secretary of Federal Signal Corp /De/, sold 19,264 shares of common stock on August 3, 2026.
NASDAQ
Jorn Drappa, Chief Medical Officer of Alumis Inc., sold 2,447 shares of common stock on August 3, 2026 for $26.37 per share.
NYSE
William J.G. Griffith, a Director and 10% owner of Procore Technologies, Inc., reported multiple transactions in common stock on August 3, 2026.
NASDAQ
Kameel D. Farag, Interim CFO of Akari Therapeutics Plc, received 1,130 shares of common stock on July 16, 2026.
NASDAQ
Gili Brudno, Chief Human Resources Officer of Playtika Holding Corp., reported multiple transactions in common stock on August 4, 2026.
NYSE
John Steinmetz, Fmr Exec Mng Dir of Strat Init of National Bank Holdings Corp, reported multiple transactions in common stock on August 5, 2026.
NYSE
ICONIQ Strategic Partners III, L.P. and 6 others reported changes in beneficial ownership of Procore Technologies, Inc. common stock on August 3, 2026.
NASDAQ
Benjamin Stone, Chief Business Officer of First Tracks Biotherapeutics, Inc., received 60,492 shares of common stock on August 2, 2026.
NASDAQ
Paul F. Lizzul, Chief Medical Officer of First Tracks Biotherapeutics, Inc., received 60,492 shares of common stock on August 2, 2026.